Characterization of YY1 OPB Peptide for its Anticancer Activity

Author(s): Yige Qi, Ting Yan, Lu Chen, Qiang Zhang, Weishu Wang, Xu Han, Dangdang Li, Jinming Shi, Guangchao Sui*.

Journal Name: Current Cancer Drug Targets

Volume 19 , Issue 6 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Background: The oncoprotein binding (OPB) domain of Yin Yang 1 (YY1) consists of 26 amino acids between G201 and S226, and is involved in YY1 interaction with multiple oncogene products, including MDM2, AKT, EZH2 and E1A. Through the OPB domain, YY1 promotes the oncogenic or proliferative regulation of these oncoproteins in cancer cells. We previously demonstrated that a peptide with the OPB sequence blocked YY1-AKT interaction and inhibited breast cancer cell proliferation.

Objective: In the current study, we characterized the OPB domain and determined a minimal region for peptide design to suppress cancer cells.

Methods: Using alanine-scan method, we identified that the amino acids at OPB C-terminal are essential to YY1 binding to AKT. Further studies suggested that serine and threonine residues, but not lysines, in OPB play a key role in YY1-AKT interaction. We generated GFP fusion expression vectors to express OPB peptides with serially deleted N-terminal and found that OPB1 (i.e. G201-S226) is cytoplasmic, but OPB2 (i.e. E206-S226), OPB3 (i.e. E206-S226) and control peptide were both nuclear and cytoplasmic.

Results: Both OPB1 and 2 inhibited breast cancer cell proliferation and migration, but OPB3 exhibited similar effects to control. OPB1 and 2 caused cell cycle arrest at G1 phase, increased p53 and p21 expression, and reduced AKT(S473) phosphorylation in MCF-7 cells, but not in MDA-MB-231 cells.

Conclusion: Overall, the serines and threonines of OPB are essential to YY1 binding to oncoproteins, and OPB peptide can be minimized to E206-S226 that maintain inhibitory activity to YY1- promoted cell proliferation.

Keywords: YY1, OPB peptide, protein interaction, inhibitory activity, anticancer activity, oncoproteins.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 6
Year: 2019
Page: [504 - 511]
Pages: 8
DOI: 10.2174/1568009618666181031153151
Price: $58

Article Metrics

PDF: 8